Zhitong Financial App News, Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the China National Drug Administration, agreeing to carry out HP568 tablets to treat advanced breast cancer (ER+ER2) positive and human epidermal growth factor receptor 2 (Human Epidermal Growth Factor Receptor, HER2) negative advanced breast cancer) clinical trial. According to inquiries, as of the disclosure date of this announcement, no similar PROTAC products at home or abroad have been approved for listing.

Zhitongcaijing · 10/15 10:17
Zhitong Financial App News, Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the China National Drug Administration, agreeing to carry out HP568 tablets to treat advanced breast cancer (ER+ER2) positive and human epidermal growth factor receptor 2 (Human Epidermal Growth Factor Receptor, HER2) negative advanced breast cancer) clinical trial. According to inquiries, as of the disclosure date of this announcement, no similar PROTAC products at home or abroad have been approved for listing.